由于强烈的安全性结果,PentixaTher在试验中获得了更高剂量的治疗. PentixaTher, a new AML treatment, advanced to a higher dose in trials due to strong safety results.

Pentixapharm报告说,在7.5GBq剂量取得积极安全效果之后,其实验性放射标签疗法PenttixaTher在急性流血性白血病(AML)第1/2阶段试验中,已进入五种计划剂量水平中的第四种水平。 Pentixapharm reports that its experimental radiolabeled therapy PentixaTher has moved to the fourth of five planned dose levels in a Phase 1/2 trial for acute myeloid leukemia (AML), following positive safety results at the 7.5 GBq dose. 独立的数据安全监测委员会批准升级为10GBq,这表明安全情况可以管理。 The independent Data Safety Monitoring Board approved escalation to 10 GBq, indicating a manageable safety profile. 这项由南特大学医院主导,并由法国卫生部资助的试验旨在评估治疗在AML患者的安全性,耐受性和早期有效性,AML患者的治疗选择有限,五年生存率约为32%至37%. The trial, led by University Hospital of Nantes and funded by the French Ministry of Health, is evaluating the treatment’s safety, tolerability, and early effectiveness in AML patients, a disease with limited options and a five-year survival rate of about 32% to 37%. PentixaTher的目标是CXCR4, 一种在反洗钱细胞中表现过度的受体,使用177-将辐射直接送到癌症细胞。 PentixaTher targets CXCR4, a receptor overexpressed in AML cells, using 177-lutetium to deliver radiation directly to cancer cells. 如果安全继续,审判将进行到12.5GBq的最后剂量水平。 If safety continues, the trial will proceed to the final dose level of 12.5 GBq. 研究人员和公司领导认为，这一进展是扩大晚期 AML 治疗选择的潜在一步。 Researchers and company leaders view the progress as a potential step forward in expanding treatment options for advanced AML.